Markets
markets
Luke Kawa

IonQ posts huge sales beat in Q3

IonQ posted a monster top-line beat in the third quarter, along with a smaller loss than analysts had feared.

The results:

  • Revenue: $39.9 million (compared to a consensus estimate of $27 million and guidance for $27 million)

  • Adjusted earnings per share: -$0.17 (estimate: -$0.31)

Management boosted its full-year revenue outlook to a range of $106 million to $110 million (previously $82 million to $100 million).

Shares are up nearly 4% in premarket trading on Thursday morning.

“We believe the growing momentum across a variety of applications reflects IonQ's transformation into a full-stack quantum computing platform company,” writes Needham analyst N. Quinn Bolton. “Notably, management believes that providing a QC platform will enable the company to pursue ‘triple-digit million-dollar’ awards over time.”

The prospect of government support has been a major catalyst for the quantum space in recent months, including the US government deeming the technology an R&D priority, which was followed by a report that the Trump administration was in talks to accumulate equity stakes in IonQ and its peers. That report, however, was quickly contradicted by separate reports.

Over the course of the third quarter, IonQ signed an agreement with the Department of Energy to advance the development and deployment of quantum technology in space, and also announced plans to acquire quantum sensor company Vector Atomic. It carried some of this momentum through early in Q4, claiming a “quantum computing world record” for the accuracy of its two-qubit gate model.

Shares of the trapped ion pure-play quantum computing company peaked at nearly $85 in mid-October, but slumped into the mid-$50s ahead of this report as part of a broad pullback across many speculative pockets of the market.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.